Analyst Research
| Report Title | Price |
|---|---|
|
Provider: Pechala's Reports
|
$15.00
|
|
Provider: Reuters Investment Profile
|
$20.00
|
|
Provider: Thomson Reuters Stock Report
|
$25.00
|
|
Provider: ValuEngine, Inc.
|
$127.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Myriad Genetics Inc Reaffirms FY 2013 Revenue Guidance-Conference Call
Myriad Genetics Inc announced that its fiscal 2013 guidance is for total revenues of $570 million to $585 million. According to I/B/E/S Estimates, analysts on an average are expecting the Company to report revenue of $580 million for fiscal 2013.
Latest Key Developments in Advanced
- Waters Corp Issues FY 2013 Revenue Guidance In Line With Analysts' Estimates; Reaffirms FY 2013 EPS Guidance-Conference Call
- Hologic Inc Updates FY 2013 Guidance To A Range In Line With Analysts' Estimates-Conference Call
- Arrhythmia Research Technology Inc Issues Q1 2013 Guidance; Announces Delay In Finalizing First Quarter Of 2013 Results
- Biosensors International Group Ltd Announces Incorporation Of New Subsidiaries
- Share this
- Link this
- Digg this
Follow Reuters